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Abstract
Background: High levels of estrogens during pregnancy not only retard placental and fetal growth
but can lead to reproductive tract abnormalities in male progeny. Estrogens act through estrogen
receptors (ER) to modulate the transcription of target genes. These ER exist in two isoforms, ER
alpha and ER beta and recently several variants of these isoforms have been identified.
Methods: The expressions of ER isoforms and variants have been studied in rat placenta at 16, 19
and 21 days gestation (dg). Gene expression was assessed using RT-PCR and real time PCR while
protein expression was studied using Western blotting followed by immunodetection. Placental
homogenates were probed with: a monoclonal antibody raised against the steroid binding domain
of the ER alpha (ER alpha -S), a monoclonal antibody raised against the hinge region of ER alpha (ER
alpha -H) and a polyclonal antibody raised against the amino terminus of ER beta.
Results: ER alpha and ER beta mRNA and protein were detected from as early as 16 dg. Two PCR
products were detected for ER alpha, one for the wild type ER alpha, and a smaller variant. Real
time PCR results suggested the presence of a single product for ER beta. The antibodies used for
detection of ER alpha protein both identified a single 67 kDa isoform; however a second 54 kDa
band, which may be an ER alpha variant, was identified when using the ER alpha -H antibody. The
abundance of both ER alpha bands decreased significantly between 16 and 19 dg. As for ER beta,
four bands (76, 59, 54 and 41 kDa) were detected. The abundance of the 59 and 54 kDa bands
decreased significantly between 16 and 19 dg.
Conclusion: This study shows that both ER protein isoforms and their variants are present in rat
placenta. The decrease in their expression near parturition suggests that the placenta may be
relatively unresponsive to estrogens at this stage.
Background
Placental growth and function are of biological signifi-
cance in that placental tissue promotes prenatal life and
pregnancy maintenance. In many mammalian species the
placenta produces estrogens during pregnancy suggesting
a role for placental estrogens as paracrine factors in the
regulation of placental growth and differentiation [1].
However, in contrast to the human placenta, which plays
a role in producing progesterone and estrogen, the rat pla-
centa does not produce estrogen [2,3] and secretes only
small amounts of progesterone [4]. Indeed the rat pla-
centa is the principal source of testosterone in the periph-
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eral circulation between days 14–18 of pregnancy [5] and
this testosterone serves as the substrate for estradiol syn-
thesis in the corpus luteum [6]. Thus although the rat pla-
centa does not produce estradiol it sustains the ovarian
production of this hormone.
Estrogen and progesterone are both essential for the initi-
ation and maintenance of pregnancy in the rat. With
regard to progesterone, growth and development of the
embryo and fetus are unaffected over a wide range of pro-
gesterone concentrations in maternal plasma [7]. On the
other hand, pharmacological doses of estrogens cause
high levels of embryonic mortality [8], although adminis-
tration later in pregnancy causes retarded fetal growth
with less effect on survival [9].
In order for estrogens to exert their biological effects, they
need to bind to the ER which then undergoes a conforma-
tional change allowing it to interact with chromatin and
to modulate transcription of target genes [10]. ER exists in
two different isoforms, ER alpha and ER beta (ERα and
ERβ) [11-13]. Both proteins are physiologically relevant,
they bind estradiol with high affinity and activate tran-
scription of estrogen responsive reporter gene constructs
expressed in mammalian cell lines [11,14].
There is increasing concern over the known effects of var-
ious chemicals released into the environment on the
reproduction of humans and other species. It is well
known that gonadal steroids function as organizational
agents during fetal development and thus exposure of the
developing fetus to exogenous estrogens can cause long
term deleterious effects. This led to the assumption that a
possible cause for the rise in male reproductive tract
abnormalities may be the inappropriate exposure to estro-
gens or suspected environmental estrogenic chemicals
during fetal and/or neonatal life [15,16]. The estrogenic
potency of industrial-derived estrogenic chemicals is lim-
ited but the estrogenic potency of phytoestrogens is signif-
icant, especially for ERβ and may trigger many of the
biological responses that are induced by the physiological
estrogens [17].
The present study was therefore designed to: 1) investigate
whether ER proteins are present in rat placentae and 2) to
test the hypothesis of whether maternal estrogens act as
local regulatory factors on ER mRNA and protein expres-
sion. Accordingly, estrogen receptor alpha and beta
mRNA and protein expression was studied in rat placen-
tae at different days gestation. In this article we have dem-
onstrated that both ER isoforms (ERα and ERβ) are
expressed in rat placentae as early as 16 dg and that these
isoforms and some of their variants (term used in this arti-
cle to refer to the subtypes of each isoform) tend to
decrease with progression of pregnancy probably due to
the high levels of sex steroids towards term.
Materials and methods
Materials
The polyclonal antibody corresponding to amino acids 1–
150 of the ERβ was purchased from Santa Cruz Biotech-
nology, Inc., U.S.A (catalogue # H-150; sc-8974). Two
monoclonal antibodies raised against different epitopes
of the ERα were used: one raised against the steroid bind-
ing domain of the ERα (amino acid residues 495–595;
referred to as ERα-S; catalogue # C-311; Santa Cruz Bio-
technology, Inc., U.S.A) and the other raised against the
hinge region (amino acid residues 287–300; referred to as
ERα-H; catalogue # SRA-1000; Stressgen Biotechnologies
Corp., Canada). The actin monoclonal antibody was pur-
chased from Santa Cruz Biotechnology, Inc., U.S.A (cata-
logue # C-2). PVDF membranes were obtained from
Amersham Pharmacia Biotech Ltd., U.K.
Animals
Sprague-Dawley rats were obtained from Bantin and King-
man (U.K.). The rats were housed in the Animal Resources
Centre at the Faculty of Medicine, Kuwait University and
had free access to food and water. The rats were main-
tained on a cycle of 12 h light and 12 h darkness at 22°C.
The experiments were carried out in accordance with the
rules of laboratory animal care in this institution.
Tissue collection
Female rats were mated with males and mating was veri-
fied by the presence of sperm in the vaginal smear; this
was designated as day 0 of pregnancy. Pregnant dams were
stunned and killed by cervical dislocation at 16, 19 or 21
days gestation (dg). Uterine horns containing conceptuses
were removed and placed immediately on ice. Fetuses and
placentae were separated and placental tissues from each
litter were pooled (four pregnancies were obtained at each
gestational age [n = 4] and three to four placental tissues
per pregnancy were pooled). The maternal uterus and
maternal brain of the 21 dg dams were used as a positive
control (data not shown). The cryoprotective agent,
dimethylsulfoxide, (10% v/v) was added before freezing
at -70°C for subsequent analysis.
RNA isolation and quantification
Samples were homogenized in denaturing solution (4 M
guanidine thiocyanate salt, 25 mM sodium citrate, pH
7.0, 0.5% w/v sarcosyl and 0.1 M 2-mercaptoethanol)
using a sterile hand-held homogenizer. To 3.6 ml
homogenate, 0.36 ml sodium acetate (2 M, pH 4.0), 3.6
ml citrate buffer-saturated phenol (pH 4.3) and 0.72 ml
chloroform:isoamyl alcohol (49:1) were added sequen-
tially, shaking well between each addition. Tubes were
vigorously shaken for 15 s after the final addition. TubesReproductive Biology and Endocrinology 2006, 4:13 http://www.rbej.com/content/4/1/13
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were kept on ice for 15 min, then centrifuged (10,000 g
for 20 min at 4°C). The aqueous phase was removed,
avoiding the DNA interphase, and an equal volume of ice-
cold isopropanol was added. After shaking, tubes were
kept at -20°C for > 1 h. The precipitate was collected by
centrifugation (10,000 g for 20 min at 4°C) and dissolved
in 0.3 ml denaturing solution. Nucleic acid was re-precip-
itated by adding an equal volume of ice cold-isopropanol.
After > 1 h at -20°C, the samples were centrifuged (10,000
g for 10 min at 4°C). The pellet was washed twice with 1
ml 75% (v/v) ethanol (at -20°C) by suspension/centrifu-
gation. The final pellet was air-dried, then dissolved in
0.5% (w/v) SDS (0.25 µl/mg wet weight tissue) at 65°C
for 15 min. Extracted RNA was stored at -70°C. The qual-
ity and quantity of total RNA sample was determined
using spectroscopic measurements at 260 and 280 nm.
Samples with A260/A280 ratios > 1.7 were only studied fur-
ther. The integrity of total RNA was checked by agarose gel
electrophoresis and 28S and 18S rRNAs visualized after
ethidium bromide staining.
Reverse Transcription Polymerase Chain Reaction (RT-
PCR)
SDS was removed from total RNA by precipitation with
sodium acetate-isopropanol then resuspended (at ca. 1
µg/µl) in water. The RNA concentration was determined
by spectrophotometery and was adjusted to 0.5 µg/µl with
water. All samples were DNase treated before reverse tran-
scription. Briefly, 2 µg of total RNA was mixed on ice with
40 U of RNasin, 1 U of DNase and 1× DNase buffer in a
final volume of 20 µl. The mixture was left at room tem-
perature for 15 min and the reaction was terminated by
adding 2 µl of 25 mM EDTA and heating at 70°C for 10
min. The DNase-treated sample was divided into two 11
µl aliquots, 100 ng random hexamers were added and the
mixture was heated at 70°C for 10 min, immediately
chilled on ice for > 3 min then briefly centrifuged. With
the tube on ice, the following were added: 1× first strand
buffer (25 mM Tris-HCl pH 8.3, containing 37.5 mM KCl
and 1.5 mM MgCl2), 5 mM DTT and 500 µM dNTP mix.
To one tube (RT+ reaction) 200 U Superscript II RNase H-
reverse transcriptase were added, whereas water was
added to the other tube (control RT-reaction) in a final
volume of 20 µl. After gentle mixing, reactions were incu-
bated at room temperature for 10 min then at 42°C for 50
min. Reactions were terminated by heating at 70°C for 15
min.
The PCR reaction was carried out in a programmable ther-
mal cycler (Perkin Elmer, model 9700). The ERα primer
sets used were rERα U (5'-TAAGAACCGGAGGAA-
GAGTTG) and rERα L (5'-TCATGCGGAATCGACTTG)
that give an expected 623 bp product. The 18S housekeep-
ing gene primer sets r18S U (5'-GTCCCCCAACTTCTTA-
GAG) and r18S L (5'-CACCTACGGAAACCTTGTTAC) give
an expected 419 bp product. The reaction mixture con-
sisted of: 1× PCR buffer (20 mM Tris/50 mM KCl), 3 mM
MgCl2, 0.5 mM dNTPs and 0.3 µM each of upper and
lower primers, 0.5 µl template (RT+, or RT- in addition to
a water sample used as a negative control) and 1.25 U
recombinant Taq DNA polymerase in a final volume of 25
µl. The PCR reactions were then cycled as follows: 5 min
at 94°C (1 cycle); 30 s at 94°C (denaturation step), 30 s
at the 45°C (annealing step) and 1 min at 72°C (exten-
sion step) for the required number of cycles (24 cycles for
18S and 32 cycles for ERα). Tubes were then incubated for
a further 7 min at 72°C (1 cycle).
Real Time PCR (ReT-PCR)
The ReT-PCR reaction was carried out in a ReT-PCR system
(Applied Biosystems, model 7500). The endogenous con-
trol, β-glucuronidase, used in this experiment was sup-
plied by Applied Biosystems. The ERβ primer sets used
detect both the wild type and a variant that has a 54 bp
(18aa) in-frame sequence between exons 5 and 6 of wild
type ERβ [18]. These primer sets were rERβ LBD U (5'-
GAGCTCAGCCTGTTGGACC) and rERβ LBD L (5'-
GGCCTTCACACAGAGATACTCC) [19]. The PCR reac-
tions were prepared using the Taq Man universal master
mix (# 4324018, Applied Biosystems) then cycled as fol-
lows: 2 min at 50°C (1 cycle); 10 min at 95°C (1 cycle),
15 s at 95°C and 1 min at 60°C for 60 cycles.
Isolation of proteins and western blot analysis
Placentae were thawed and washed twice with ice-cold
isotonic saline then homogenized in ice-cold homogeni-
zation buffer containing glycerol [to stabilize the recep-
tors] and protease inhibitors (10 mM Tris-HCl pH 7.4, 1.5
mM EDTA and 10% v/v glycerol, 1.0 mM DTT, 1 µg/ml
leupeptin, 100 µg/ml bacitracin, 2 µg/ml aprotonin, 1 µg/
ml pepstatin A), using a Polytron homogenizer, to yield a
5% (w/v) homogenate (the total receptor fraction).
Homogenates were passed through a nylon mesh (110
µm pore size) then through steel gauze (40 µm pore size).
An aliquot was removed for protein assay. Samples (50–
100 µg protein) and molecular weight rainbow markers
(14,300 – 220,000 daltons; Amersham Pharmacia Bio-
tech Ltd., U.K.) were mixed with loading buffer (0.03% w/
v bromophenol blue, 32 mM Tris-HCl pH 6.8, 8% w/v
dithiothreitol and 4% w/v SDS), boiled for 5 min, then
chilled on ice and centrifuged (10,000 × g for 1 min).
Samples were then electrophoresed (SDS PAGE; 7.5%
polyacrylamide gels). The distance migrated by the
marker proteins and bromophenol blue front were meas-
ured. The buffer chamber of the electrophoresis apparatus
was filled with degassed transfer buffer (25 mM Tris-HCl,
150 mM glycine, 20% v/v methanol and 0.1% w/v SDS,
pH 8.3). Gels were equilibrated in transfer buffer then
protein was transferred to PVDF membranes with a con-Reproductive Biology and Endocrinology 2006, 4:13 http://www.rbej.com/content/4/1/13
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stant current of 300 mA overnight with cooling. After
transfer the membranes were dried and stored at 4°C.
Immunodetection
Membranes were blocked for 1 h at room temperature
with 10% non-fat dry milk in TBS-T (20 mM Tris, 137 mM
NaCl, pH 7.6 and 0.1% v/v Tween). The membranes were
washed by rinsing twice with TBS-T, followed by two 10
min washes (20 ml/wash). Membranes were then incu-
bated overnight at 4°C with 3 ml primary antibody solu-
tion diluted in 5% w/v non-fat dry milk in TBS-T (ERα-S
diluted 1:500, ERα-H diluted 1:1000 and ERβ antibody
diluted 1:1000). After incubation, the membranes were
rinsed twice with TBS-T followed by one 15 min wash and
two 5 min washes (20 ml/wash). Membranes were incu-
bated with the appropriate secondary antibody (anti-
mouse Ig HRP linked diluted 1:20000 or anti-rabbit Ig
HRP linked diluted 1:10000 in TBS-T) for 1.5 h at room
temperature then rinsed twice with TBS-T followed by one
15 min wash and four 5 min washes (20 ml/wash). Detec-
tion was by chemiluminescence after incubation with an
HRP-linked secondary antibody – using a commercial kit
(ECL-Plus; Amersham Pharmacia Biotech Ltd., U.K.) and
standard methodology. After obtaining the results for the
respective estrogen receptor primary antibodies, the mem-
branes were stripped in stripping buffer (100 mM 2-mer-
captoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7) at
50°C for 30 min with occasional shaking. The mem-
branes were then washed twice in TBS-T for 10 minutes
each before being re-probed with anti-actin antibody
(diluted 1:500 in TBS-T) which served as an internal con-
trol. All results were expressed relative to actin.
Protein determination
Protein was determined by a dye-binding method using
Coomassie Plus Protein assay reagent (Pierce & Wariner
Ltd, U.K.)
Determination of protein sizes
In order to determine the sizes of the bands a marker lane
was always included. The distance migrated by the protein
marker was measured and a standard curve constructed
using a plot of log10 molecular mass versus relative mobil-
ity (distance migrated by band ÷ distance migrated by dye;
Rf). The size of the unknown protein band was then deter-
mined using the equation of the line.
Data analysis
After the RT-PCR reaction for ERα, PCR products were
electrophoresed alongside a 100 bp DNA marker (100 bp
ladder, Gibco), through a 2% (w/v) low electroendosmo-
sis (LE; Boehinger Manheim) agarose gel stained with
ethidium bromide. All images were captured using Gene
Genius Bio Imaging System and od values of PCR prod-
ucts were measured using Gene Tools Software. As for
ReT-PCR the results for the average CT threshold cycle for
each sample was used to express the relative expression of
ERβ to β-glucuronidase.
Statistical analysis was performed using SPSS (ANOVA
followed by post-hoc analysis [LSD]) when the test for
homogeneity of variance was fulfilled and using Games-
Howell post-hoc analysis when the homogeneity of vari-
ances was not attained. All data shown are mean ± S.E.M.
and a p value of < 0.05 was taken as the minimum level of
significance.
Results
Gross parameters
As expected there was a significant increase (p < 0.001) in
placental weights and fetal body weights with gestation
(Table 1). As for the litter number, there was a significant
decrease (p < 0.001) between 16 and 21 dg and fetal
resorptions were detected in some dams, however, these
dams were not included in this study.
Protein concentration and content
There was no significant change in placental protein con-
centration (Table 1), nevertheless, a significant increase in
protein content was observed between 16 and 19 dg (p <
0.001). This increase was in parallel with the increase in
placentae weight noticed with gestation (Table 1).
Estrogen receptor alpha gene expression
The expected PCR product (623 bp) for the ERα mRNA
was detected in rat placentae from as early as 16 dg (Figure
Table 1: Litter size, feto-placental growth and placental protein measurements.
Days gestation (dg) Litter number Placentae weights (g) Fetal body weights (g) Protein 
concentration 
(mg/g wet wt)
Protein content 
(mg/tissue)
16 12 ± 1 0.313 ± 0.010 0.513 ± 0.016 90.904 ± 3.559 28.489 ± 1.893
19 11 ± 1 0.508 ± 0.012* 2.371 ± 0.060* 98.004 ± 3.476 49.709 ± 1.014*
21 9 ± 1* 0.546 ± 0.007* 5.387 ± 0.166* 95.307 ± 3.713 52.053 ± 2.037*
Values are mean ± S.E.M. for four different dams. A significant increase (p < 0.001) in placental and fetal body weights during gestation and a 
significant decrease (p < 0.001) in litter number between 16 and 21 dg was detected. Placental protein concentration was measured using the 
Bradford method; a significant increase in protein content was observed between 16 and 19 dg and 16 and 21 dg (*p < 0.001; LSD test).Reproductive Biology and Endocrinology 2006, 4:13 http://www.rbej.com/content/4/1/13
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1). However, a ~500 bp product was also detected from 16
dg. The RT- and W reactions did not show any bands (fig-
ures not shown), indicating that the amplified products in
RT+ reactions are not due to genomic DNA nor due to
contamination of reagents, respectively. The od measure-
ments of PCR products obtained for ERα gene were
expressed relative to the od obtained from 18S. When
expressed relative to the 18S housekeeping gene it was
seen that the pattern of expression of both products rela-
tive to 18S was similar with a significant decrease in ERα
mRNA expression between 16 and 21 dg and 19 and 21
dg (*p < 0.001).
Estrogen receptor beta gene expression
Using RT-PCR it was not possible to detect ERβ mRNA
expression. However, using ReT-PCR it was possible to
amplify the ERβ gene (Figure 2). The average threshold
cycle (CT) for duplicate samples was expressed relative to
that of β-glucuronidase (endogenous or housekeeping
gene). No significant change in ERβ gene expression was
detected with gestation.
Estrogen receptor alpha protein expression
A ~67 kDa single band for ERα was observed for the pla-
cental samples using both the ERα-H and the ERα-S anti-
bodies from as early as 16 dg (Figures 3 &4, respectively).
However, using the ERα-H antibody, another band of
apparent molecular weight of 54 kDa was detected. The
abundance of these ERα variants decreased significantly
between 16 and 19 dg (p < 0.05) as shown when the ERα-
H antibody was used. However, using the second anti-
body, ERα-S, no apparent change in protein expression
was observed although the level at 19 dg appeared lower
but did not reach significance. The 54 kDa band observed
with the ERα-H antibody was more abundant at 16 dg
compared to the 67 kDa (Figure 3). This difference in
expression was normalized by 19 dg.
Estrogen receptor beta protein expression
When studying the expression of the second estrogen
receptor isoform, ERβ, four bands were detected with
apparent molecular weights of 76, 59, 54 and 41 kDa (Fig-
ure 5). When comparing the level of expression of the ERβ
protein as pregnancy progressed, it was found that there
was a significant decrease in expression of the 59 and 54
kDa bands (p < 0.001) between 16 and 19 dg. Moreover,
the 76 kDa band showed a tendency to decrease at 19 dg,
however, this was not statistically significant. On the
other hand, the 41 kDa ERβ variant showed a different
pattern of expression with a trend to increase between 16
and 19 dg (not statistically significant).
Discussion
In this study dams were sacrificed at 16, 19 and 21 dg, the
number of fetuses was determined, placentae were col-
lected and ER status was verified both at the mRNA and
protein levels. It was rather interesting to observe that as
pregnancy advanced there was a reduction in litter size
Expression of ERα transcript in rat placentae during gesta- tion Figure 1
Expression of ERα transcript in rat placentae during 
gestation. [A] Ethidium bromide stained gel for ERα. The 
migration of the 100 bp marker (M) is shown on the left-
hand side and the calculated size of the signal indicated on 
the right-hand side of the gel (expected size is 623 bp). An 
extra ~500 bp band was detected for ERα. Both RT- and 
water samples were negative (data not shown). Reactions 
were performed for 32 cycles at 45°C, using standard reac-
tion conditions. [B] Ethidium bromide stained gel for 18S. 
The migration of the 100 bp marker (M) is shown on the left-
hand side and the calculated size of the signal indicated on 
the right-hand side of the gel (expected size is 419 bp). Both 
RT- and water samples were negative (data not shown). 
Reactions were performed for 24 cycles at 45°C, using 
standard reaction conditions. [C] Relative ERα mRNA level. 
The amount of product was expressed relative to 18S. Sam-
ples were run in duplicates; results shown are mean ± S.E.M. 
(n = 4). A significant decrease in ERα mRNA expression was 
detected between 16 and 21 dg and 19 and 21 dg for both 
PCR products (*p < 0.001).
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number. This decrease has been explained by other inves-
tigators, studying various animal models, as being possi-
bly due to fetal resorptions, a reduction in the number of
maturing follicles, and/or atrophy of ovaries [20,21]. In
our study fetal resorptions were observed in some preg-
nancies, however, when this was the case these animals
were excluded from the study.
The differentiation and growth of the rat chorioallantoic
placenta occurs between days 8 through 21 and the
expression of ER was studied between 16 and 21 dg. How-
ever, before studying the expression of the ER isoforms in
placental samples, the protein concentration was deter-
mined. Placental protein concentration showed no signif-
icant change with gestation, however, the increase in
placental weight was accompanied by an increase in pro-
tein content. This increase may have resulted from altera-
tions in protein metabolism or cell gain.
It was clear when studying the expression of ERα and ERβ
mRNA that there was a reduction in ERα mRNA by 21 dg;
however, there was no change in ERβ mRNA expression
with progression of pregnancy. A similar pattern for ERα
and ERβ mRNA was reported in rat corpus luteum during
pregnancy. The levels of ERα mRNA increased from early
pregnancy, reached a maximum at mid-pregnancy and
declined before parturition while levels of ERβ mRNA
remained constant throughout pregnancy, with a signifi-
cant decline at parturition [22]. Similarly a decline in ERα
mRNA between days 11 and 16 of pregnancy was detected
in rat decidua basalis [23].
To study whether the changes in gene expression reflect
changes in protein, the expression of ERα and ERβ pro-
teins were studied. For ERα, two antibodies were used,
one raised against the hinge region of the ERα (ERα-H)
and another against the steroid binding domain (ERα-S).
It was found that when using the ERα-H antibody, two
bands of apparent molecular weights of 67 and 54 kDa
were detected, while when using the ERα-S antibody only
the 67 kDa bands was identified. According to the suppli-
ers, the ERα-H antibody does not recognize the native ER
in the inactive 8S but reacts efficiently with the activated
4S receptor and thus it may be that both the 67 and 54
kDa variants are activated forms of the ERα protein.
Although studies have shown the expression of ERβ mes-
senger RNA (mRNA) in various tissues, the expression of
this ER isoform has not been studied extensively at the
protein level in placentae using Western blotting method-
ologies. In our study, four discrete bands were detected for
ERβ with apparent molecular weights of 76, 59, 54 and 41
kDa. The 59 kDa band has been reported as the full length
ERβ [24-26] while the 54 kDa [12,14] and the 41 kDa
bands, may be truncated variants of the ERβ isoform
[18,24,27]. On the other hand, the higher molecular
weight 76 kDa protein band, may indicate that posttrans-
lational modification, such as phosphorylation [28,29] or
glycosylation, [30,31] of the ERβ protein has taken place.
The smaller molecular weight bands, which were seen
when using the ERα-H and ERβ antibodies, could be var-
iants caused by alternative splicing, ER degradation prod-
ucts or proteins that are not related to ER but cross-react
with the antibody. The low molecular weight bands were
not detected in maternal whole brain or maternal uterus
homogenates (data not shown) indicating that they are
tissue specific. As these truncated forms were also not seen
in non-pregnant uterus [32], then they may result from
mechanisms unique to uterine stroma during pregnancy.
In mice it has been shown that estradiol induces protein-
Expression of ERβ transcript in rat placentae during gestation Figure 2
Expression of ERβ transcript in rat placentae during 
gestation. [A] ReT-PCR analysis for ERβ and β-glucuroni-
dase. A graph showing delta Rn (change in normalized 
reporter expression) as a function of cycle number. Reac-
tions were performed for 60 cycles at 60°C, using recom-
mended conditions by supplier. Samples were run in 
duplicates for both target and endogenous genes. [B] Relative 
ERβ gene expression. The average threshold cycle (CT) for 
duplicate samples was expressed relative to that of β-glu-
curonidase. Results shown are mean ± S.E.M. (n = 4). No sig-
nificant change in ERβ gene expression was detected.
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ase activities that degrade ER from a 65 kDa molecule to a
54 kDa variant [33]. Thus, the level of ER existing in target
cells is dynamic and is probably under fine control by rap-
idly turning over proteinases, signifying an important
posttranslational regulatory mechanism [32,33]. Post-
translational modification of ER could therefore be a
common, albeit not appreciated, mechanism by which a
target cell may regulate its responsiveness to estradiol.
There was a clear decline in ERα protein expression when
the antibody that was raised against the hinge region was
used. In fact the abundance of both the ERα variants (67
and 54 kDa) decreased significantly between 16 and 19
dg. Telleria et al. [22] has also shown that the antibody ER-
715, raised against the hinge region of the rat, detected
two bands 67 and 61 kDa; the 67 kDa variant was highly
expressed at mid-pregnancy but barely detectable in early
and late gestation while the 61 kDa variant remained
unchanged. When using the antibody that was raised
against the steroid binding domain, a significant decrease
in the ERα protein expression was not detected, but there
was a trend for the levels to decrease by 19 dg. The inabil-
ity to reach significance may be due to the fact that this
antibody is recognizing both the active and inactive recep-
tors whereas the ERα-H recognized only the activated
receptor, which is down-regulated as shown by the
decrease in levels between 16 and 19 dg. Thus, the results
using the ERα-S, which detects the total (inactive and
active) receptor content, are influenced by the presence of
the inactive receptor form which may not be down-regu-
lated with gestation thereby biasing the overall result.
The decrease in abundance of the 59 and 54 kDa ERβ var-
iants between 16 and 19 dg clearly indicate that there is
down-regulation of the receptors. Although the 76 kDa
variant showed a tendency to decrease at 19 dg this was
not statistically significant. On the other hand, the 41 kDa
ERβ variant showed a different pattern of expression with
a tendency to increase between 16 and 19 dg but this also
failed to reach statistical significance. The 41 kDa ERβ var-
iant is probably derived from the native 59 kDa moiety as
it wasn't extensively expressed and yet became the domi-
nant form as the levels of the native ER decreased and it
may be one of many forms of degradation fragments that
happened to contain the anti-ERβ epitope. These thus far
unreported bands may be tissue specific and may have
certain yet unidentified functions in the placenta.
It has been shown by several investigators that total estro-
gen concentrations in blood rise markedly during human
[34-36] pregnancies. In addition, we have shown that
estradiol levels rise during pregnancy from 33 pg/ml at 16
dg to 39 pg/ml at 21 dg (unpublished data). The decrease
in ER protein expression between 16 and 19 dg may be
due to down-regulation of the receptors by the high con-
centration of estradiol in pregnant dams towards the end
of gestation [37,38] since down-regulation of hormone
receptors by their ligands has been reported for steroid
hormones [37,39]. This decrease in ER expression near
parturition suggests that placentae are relatively unre-
sponsive to estrogens at this stage, which agrees with stud-
ies shown by others on bovine [40] and human [41]
placenta. In order for down-regulation to take place, high
levels of estradiol concentrations ≥ 0.5 mg/ml are required
[37]. It has been reported by Sheehan et al [42] that a 5.0
mg/ml estradiol implant produces a steady serum estra-
diol level of 200 pg/ml and hence 0.5 mg/ml, which
would produce an equivalent of 20 pg/ml serum estradiol,
will be sufficient to cause down-regulation of ER.
Protein expression using a monoclonal antibody (ERα-H)  raised against the ERα hinge region Figure 3
Protein expression using a monoclonal antibody 
(ERα-H) raised against the ERα hinge region. 100 µg 
of protein was loaded. [A] Representative Western blot for 
ERα and actin (which was used as an internal standard for 
normalizing the data); the calculated size of the band is indi-
cated on the left-hand side of the gel. Two bands of apparent 
molecular weights of 67 and 54 kDa were detected for ERα. 
[B] Ontogenic profile: ERα protein was expressed relative to 
actin. Results shown are mean ± S.E.M. from four different 
dams; a significant decrease in ERα protein expression was 
detected between 16 and 19 dg for the 67 kDa band (*p < 
0.05). For the 54 kDa band a significant decrease in ERα pro-
tein expression was detected between 16 and 19 dg and 16 
and 21 dg (*p < 0.05). The 54 kDa band had a higher expres-
sion at 16 dg when compared to the 67 kDa band (#p < 
0.001; LSD test).
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Progesterone decreases the quantity of uterine ER by inter-
fering with the replenishment of cytoplasmic ER thus
decreasing the sensitivity of the tissue to estrogen [43].
Reports have confirmed that progesterone lowers the lev-
els of nuclear ER when given in the presence or absence of
estradiol [39]. In a previous study, we have shown that at
16, 19 and 21 dg the levels of maternal serum estradiol
were 33, 29 and 39 pg/ml, respectively and levels in the
amniotic fluid were 117, 157 and 226 pg/ml, respectively
[44]. Furthermore, levels of progesterone in maternal
serum at 16, 19 and 21 dg were 107, 84 and 40 ng/ml,
respectively while in amniotic fluid the levels were 3, 3
and 4 pg/ml, respectively [44]. Thus the high levels of
estradiol and progesterone in both maternal serum and
amniotic fluid would therefore be a contributing factor to
the down-regulation of the estrogen receptors as preg-
nancy advanced.
It is postulated that estradiol may have a specific growth-
retarding effect on the placenta [45,46] that secondarily
limits fetal growth [47,48] and therefore, minor eleva-
tions of maternal estradiol can be fatal to the embryo.
Inhibitory action of estradiol may relate to its ability to
induce transforming growth factor mRNA [49] which in
turn encodes a protein that promotes apoptosis in decid-
ualized endometrial stromal cells [50]. Indeed, the identi-
fication of ER in rat placentae suggests that they are target
cells of estrogens. However, the decrease in estrogen
receptor protein expression with pregnancy suggests that
the placenta becomes unresponsive to estrogens pointing
towards a protective role played by the placenta to 1) min-
imize the growth retarding effects of estradiol and 2) min-
Protein expression using a polyclonal antibody (ERβ) raised  against the ERβ amino terminal Figure 5
Protein expression using a polyclonal antibody (ERβ) 
raised against the ERβ amino terminal. 25 µg of protein 
was loaded. [A] Representative Western blot for ERβ and 
actin (which was used as an internal standard for normalizing 
the data); the calculated size of the band is indicated on the 
left-hand side of the gel. Four bands of apparent molecular 
weight of 76, 59, 54 and 41 kDa were detected for ERβ. [B] 
Ontogenic profile: ERβ protein was expressed relative to 
actin. Results shown are mean ± S.E.M. from four different 
dams; a significant decrease in ERβ protein expression (p < 
0.001) was detected between 16 and 19 dg and 16 and 21 dg 
for both the 59 and the 54 kDa ERβ bands (LSD test).
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Protein expression using a monoclonal antibody (ERα-S)  raised against the ERα steroid binding domain Figure 4
Protein expression using a monoclonal antibody 
(ERα-S) raised against the ERα steroid binding 
domain. 100 µg of protein was loaded. [A] Representative 
Western blot for ERα and actin (which was used as an inter-
nal standard for normalizing the data); the calculated size of 
the band is indicated on the left-hand side of the gel. [B] 
Ontogenic profile: ERα protein was expressed relative to 
actin. Results shown are mean ± S.E.M. from four different 
dams; no significant change in protein expression was 
detected.
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imizing the possible deleterious effects of estrogens on the
developing fetus. However, further studies on the func-
tion of ER proteins in placenta will provide a better under-
standing on their role during pregnancy.
Conclusion
In this study, both ERα and ERβ isoforms and variants
were detected from 16 dg. The increase in sex steroid hor-
mone levels, reported with progression of pregnancy,
leads to down-regulation of the ER. This down-regulation
serves as a protective mechanism from the possible dele-
terious effects that high estrogen levels could have on the
developing fetus.
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